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ttps://doi.org/10.1016/j.ajpath.2018.01.011Interactions between the gut microbiota and the host are important for health, where dysbiosis has
emerged as a likely component of mucosal disease. The speciﬁc constituents of the microbiota that
contribute to mucosal disease are not well deﬁned. The authors sought to deﬁne microbial components
that regulate homeostasis within the intestinal mucosa. Using an unbiased, metabolomic proﬁling
approach, a selective depletion of indole and indole-derived metabolites was identiﬁed in murine and
human colitis. Indole-3-propionic acid (IPA) was selectively diminished in circulating serum from
human subjects with active colitis, and IPA served as a biomarker of disease remission. Administration
of indole metabolites showed prominent induction of IL-10R1 on cultured intestinal epithelia that was
explained by activation of the aryl hydrocarbon receptor. Colonization of germ-free mice with wild-type
Escherichia coli, but not E. coli mutants unable to generate indole, induced colonic epithelial IL-10R1.
Moreover, oral administration of IPA signiﬁcantly ameliorated disease in a chemically induced murine
colitis model. This work deﬁnes a novel role of indole metabolites in anti-inﬂammatory pathways
mediated by epithelial IL-10 signaling and identiﬁes possible avenues for utilizing indoles as novel
therapeutics in mucosal disease. (Am J Pathol 2018, 188: 1183e1194; https://doi.org/10.1016/
j.ajpath.2018.01.011)Supported by NIH grants DK1047893, DK50189, DK095491,
DK103639, and DK103712 (S.P.C.) and VA Merit grant BX002182
(S.P.C.). Funding for generating and maintaining the human intestinal
organoids was provided by the Bill and Melinda Gates Foundation (D.J.
Ko.).
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Disclosures: None declared.The mammalian gastrointestinal tract plays host to trillions
of microbes, collectively termed the microbiota, where a
critical mutualism exists within the intestinal mucosa. The
microbiota contributes signiﬁcantly to gut homeostasis but
can also contribute to establishing and maintaining mucosal
disease.1 Intestinal mucosal surfaces act as primary barriers
to microbial invasion, where commensal bacteria work in a
dynamic and intimate interaction with the gut epithelium
and inﬂuence host cellular and immune responses.2 In-
ﬂammatory bowel disease (IBD) is a chronic inﬂammatory
disease of the gastrointestinal tract that comprises Crohn
disease and ulcerative colitis (UC). It is known that IBD is
caused by interactions between genetic and environmental
factors, and results in perturbations of the microbiota,stigative Pathology. Published by Elsevier Incthough precisely how microbial factors affect gut homeo-
stasis and immune response have not been extensively
explored.3e5
The signiﬁcance of IL-10 signaling is well established in
IBD. This anti-inﬂammatory cytokine, which signals through
the IL-10 receptor ligand-binding subunit (IL-10R1), is
induced during inﬂammation and attenuates excessive. All rights reserved.
Alexeev et alproduction of proinﬂammatory mediators in various cell
types, including intestinal epithelial cells (IEC).6,7 Functional
IL-10 signaling is associated with enhanced mucosal barrier
function and results in maintenance and homeostasis of the
epithelia.7 Previous work, including our own, has shown that
the epithelial IL-10R1 contributes fundamentally to resis-
tance to intestinal inﬂammation and represents a component
of epithelial innate immunity originally described to be
induced by cytokines such as interferon-g (IFN-g).8 For
instance, mice deﬁcient in IL-10 or IL-10 receptor develop
spontaneous severe colitis, and mice conditionally lacking
intestinal epithelial IL-10R1 show increased susceptibility to
colitis.7,9,10
Metabolomic analysis has revealed that gut bacteria
impact host immunity through a variety of metabolites,
including indole metabolites,11 which originate from the
microbial metabolism of tryptophan. Indole-3-propionic
acid (IPA) and indole-3-aldehyde (IAld), which are trypto-
phan metabolites produced by intestinal bacteria, are known
for their intercellular signaling activity. Further, IAld has
recently been identiﬁed as an aryl hydrocarbon receptor
(AHR) ligand.12 AHR is a ligand-dependent transcription
factor activated by a variety of synthetic and biological
molecules that plays an important role in immunological
response and inhibition of inﬂammation.13 AHR contributes
to immune homeostasis through various methods, including
T-cell differentiation and Th17 development,14,15 as well as
the up-regulation of IL-22 production.16 Recently, several
studies have shown that the host microbiota provides a
consistent source of endogenous AHR ligands with distinct
effects on immune homeostasis.16e18 However, the precise
role of indole metabolites in the gastrointestinal tract re-
mains elusive. Together, these data lead us to hypothesize
that microbial-derived indole metabolites promote intestinal
homeostasis through AHR-mediated regulation of the IEC
IL-10R1.
Materials and Methods
Animal Studies
For metabolomics analysis, C57BL/6-129 mice were
administered 3% (wt/vol) dextran sodium sulfate (DSS)
(molecular weight 36,000 to 50,000; MP Biochemicals,
Burlingame, CA) in drinking water for 5 days, followed by
a 2-day recovery period. Normal tap water was returned
during these 2 days before tissue collection. Control mice
were maintained on tap water for 7 days. In subsequent
animal experiments, 8e to 12-weekeold C57BL/6 mice
were administered water or 2.5% DSS ad libitum for 9 days.
This administration approach varied slightly to account for a
change in death susceptibility to DSS. DSS was then
removed and mice were allowed to recover for 2 days before
euthanasia. For IPA treatment experiments, the addition of
IPA at 0.1 mg/mL was administered to water- and
DSS-treated animals. Mice were housed in accordance with1184guidelines from the American Association for Laboratory
Animal Care and Research Protocols, and all animal work
was approved by the Institutional Animal Care and Use
Committee of the University of Colorado.
Cell Lines and shRNA Knockdown
Human T84 IEC were cultured in 1:1 Dulbecco’s modiﬁed
Eagle’s mediumeHam’s F12 with 2.5 mmol/L L-glutamine
and 10% fetal bovine serum. Cells were maintained at 37C
with 5% CO2. Transepithelial electrical resistances were
monitored using an EVOM2Voltohmmeter (World Precision
Instruments, Sarasota, FL). Cytokines were purchased from
R&D Systems (Minneapolis, MN). IAld, IPA, and AHR in-
hibitor, CH-223191, were obtained from Sigma-Aldrich (St.
Louis, MO). 6-Formylindole[3,2-b] carbazole was obtained
from Tocris Bioscience (Bristol, UK). All compounds were
used at indicated concentrations. Human intestinal organoids
(HIOs) were derived following previously described
methods19 and kindly provided by Dr. Jason Spence (Uni-
versity of Michigan, Ann Arbor, MI). HIOs were maintained
by embedding in Matrigel (BD Biosciences, San Jose, CA)
and applying Advanced DMEM-F12 medium (Invitrogen,
Carlsbad, CA) containing 1X B27 supplement (Invitrogen),
1X GlutaMAX (Life Technologies, Carlsbad, CA), 10 mmol/
L HEPES, 10% penicillin/streptomycin, 100 ng/mL rhNog-
gin (R&D Systems), 100 ng/mL epidermal growth factor
(R&D Systems), and approximately 500 ng/mL R-Spondin1
(RSPO1). RSPO1 was obtained from conditioned media
collected from a HEK293 cell line that was stably transfected
and zeocin-selected for the RSPO1 expression vector. The
medium was changed every 2 to 4 days, and HIOs were
transferred to fresh Matrigel once a week until they reached
approximately 0.5 mm to 1 mm in size for experiments and
RNA isolation. Lentiviral particles encoding shRNA directed
against aryl hydrocarbon receptor nuclear translocator
(ARNT; TRC MISSION shRNA, University of Colorado
Functional Genomics Facility) were used to transduce T84
cells using standard protocols. Stable integration was ach-
ieved by puromycin selection at 6 mg/mL. Knockdown was
conﬁrmed by real-time quantitative PCR analysis, indicating
80% to 85% depletion of ARNT levels.
RNA Isolation and Real-Time PCR
Total RNA was extracted from cells using TRIzol (Invi-
trogen) and from tissue using RNeasy Mini Kit (Qiagen,
Hilden, Germany). cDNA was prepared using iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA). Real-time PCR to
measure transcripts was performed in 1  Power SYBR
Green Master Mix (Applied Biosystems, Foster City, CA)
using an ABI 7300 thermocycler (Applied Biosystems).
Fold-change in expression of target mRNA relative to
b-actin mRNA was calculated as previously described.20
Total RNA from HIOs was isolated using Direct-zol
RNA Miniprep Kit (Zymo Research Corp, Irvine, CA).ajp.amjpathol.org - The American Journal of Pathology
Table 1 Primer Sequences for Real-Time Quantitative PCR
Gene Forward primer Reverse primer
Human
ACTB 50-CCTGGCACCCAGCACAAT-30 50-GCCGATCCACACGGAGTACT-30
HSPCB 50-TCTGGGTATCGGAAAGCAAGCC-30 50-GTGCACTTCCTCAGGCATCTTG-30
IL10R1 50-CACATCCTCCACTGGACACC-30 50-CAAGGTCACTGCGGTAAGGT-30
SOCS3 50-GGCCACTCTTCAGCATCTC-30 50-ATCGTACTGGTCCAGGAACTC-30
CYP1A1 50-ACCCGCCACCCTTCGACAGTTC-30 50-TGCCCAGGCGTTGCGTGAGAAG-30
CYP1B1 50-CTGGCACTGACGACGCCAAGA-30 50-TGGTCTGCTGGATGGACAGC-30
MDR1 50-AACGGAAGCCAGAACATTCC-30 50-AGGCTTCCTGTGGCAAAGAG-30
Mouse
Actb 50-TACGGATGTCAACGTCACAC-30 50-AAGAGCTATGAGCTGCCTGA-30
Il10r1 50-CCCATTCCTCGTCACGATCTC-30 50-TCAGACTGGTTTGGGATAGGTTT-30
Table 2 Study Participant Demographics
Characteristic Control UC remission
Ulcerative
colitis
Number 20 20 15
Sex
Male 11 12 13
Female 9 8 2
Age, years 58.6  10.9 46.5  18.6 40.4  13.4
Disease location
Left-sided NA 6 1
Extensive NA 14 12
Proctitis NA 0 2
NA, not applicable.
Indoles and Intestinal HomeostasisFold-change in expression of mRNA transcript from HIO
experiments was calculated relative to HSPCB (heat shock
protein 90 a family class B member 1). Human and mouse
primer sequences are listed in Table 1.
Western Blot Analysis
Whole-cell and tissue lysates were extracted in Tris-Lysis
buffer on ice and disrupted by sonication. Protein content
was quantiﬁed using BCA protein assay reagent (Thermo
Fisher Scientiﬁc, Waltham, MA) and 30 mg of whole-cell or
tissue extract was boiled in Laemmli buffer in reducing
conditions subjected to SDS-PAGE. The SDS-PAGE was
transferred onto a polyvinylidene diﬂuoride membrane and
probed for IL-10R1 using a rabbit polyclonal IL-10RA
antibody (dilution 1:1000; Thermo Fisher Scientiﬁc) and
b-actin (dilution 1:10,000; Abcam, Cambridge, UK).
Metabolomic Analysis
Distal colon tissue (1 cm) was collected from control and
DSS-treated mice. Tissues were ﬂash-frozen and placed at
80C. Global metabolomics was performed by Metabolon,
Inc. (Durham, NC). Brieﬂy, tissue samples were thawed and
weighed in tared cryovials, and 80% ice-cold methanol was
added at a ratio of 75 mL of solvent per mg of sample, then
incubated overnight at 4C to extract biochemicals. Internal
standards were included to control for extraction efﬁciency.
Following methanol extraction, colon samples were pro-
cessed and analyzed as previously described.21
HPLC Metabolite Analysis
Indole derivatives were quantiﬁed in mouse and human
samples using reversed-phase high-performance liquid
chromatography with electrochemical coulometric array
detection (EC-HPLC) (CoulArray; Thermo Fisher Scienti-
ﬁc). Archived human serum samples from patients diag-
nosed with IBD or from healthy individuals were obtained
under research protocols approved by the Colorado Multi-
Institutional Review Board. Study participant demographicsThe American Journal of Pathology - ajp.amjpathol.orgare listed in Table 2. Tissue and serum samples were
extracted in 80% methanol, and protein precipitate was
removed by centrifugation at 15,000  g. Separation was
achieved using an Acclaim Polar Advantage II C18 column
(Thermo Fisher Scientiﬁc) at a ﬂow rate of 1 mL/minute on
a gradient of 10% to 55% acetonitrile in 50 mmol/L sodium
phosphate buffer (pH 3), containing 0.42 mmol/L octane-
sulphonic acid as an ion-pairing agent. Calibration curves
were composed by performing linear regression analysis of
the peak area versus the analyte concentration. The data
were quantiﬁed using the peak area in comparison to
standards.
Bacterial Strains and Gnotobiotic Colonization
Experiments
Escherichia coli (E. coli) strains were obtained from GE
Dharmacon (Lafayette, CO). An E. coli K12 parent strain
[E. coli BW25113; wild type (WT)], along with strains
containing a deletion of tnaA (E. coli JW3686; DtnaA) and
tnaB (E. coli JW5619; DtnaB) were used for experiments.
All strains were grown in Lysogeny broth (10 g/L tryptone,
10 g/L NaCl, 5 g/L yeast extract) or on Lysogeny
brotheagar plates supplemented with appropriate antibiotics
(kanamycin, 50 mg/mL), if needed. Cultures were grown
overnight at 37C to stationary phase and tested for the
presence of indole by the addition of 200 mL of Kovac’s1185
Alexeev et alreagent (Sigma-Aldrich) to 2 mL bacterial culture. For T84
cell experiments, cultures were grown overnight at 37C to
stationary phase. Brieﬂy, cultures were spun, supernatants
collected, and afterward serially diluted and placed onto cells
for 24 hours. Bacterial supernatants used for EC-HPLC
analysis were placed through a 0.22-mm ﬁlter before the run.
For gnotobiotic colonization experiments, 5- to 8-weekeold
germ-free C57BL/6 mice were gavaged with a 100-mL bac-
terial suspension for mono-association (109 colony forming
units of each bacterial strain collected from a stationary-phase
culture and re-suspended in phosphate-buffered saline). Mice
were colonized for 2 weeks before euthanasia. Fresh fecal
pellets were collected periodically, weighed, homogenized,
and then serially diluted in phosphate-buffered saline
phosphate-buffered saline for plating to determine bacterial
colony forming units per g of feces.
Histology
Colon samples were ﬁxed in 10% neutral buffered formalin
and parafﬁn embedded before staining with hematoxylin
and eosin. All histologic quantitation was performed blinded
by the same individual (S.P.C.) using a scoring system
previously described.22 Brieﬂy, the three independent pa-
rameters measured were severity of inﬂammation (0 to 3:
none, slight, moderate, severe), extent of injury (0 to 3:
none, mucosal, mucosal and submucosal, transmural), and
crypt damage (0 to 4: none, basal 1/3 damaged, basal 2/3
damaged, only surface epithelium intact, entire crypt and
epithelium lost). The score of each parameter was multiplied
by a factor reﬂecting the percentage of tissue involvement
(1: 0% to 25%, 2: 26% to 50%, 3: 51% to 75%, 4:
76% to 100%), and all numbers were summed. Maximum
possible score was 40.
Quantiﬁcation of Cytokines in Colon Tissue
For cytokine analysis, colon tissue was extracted in Tris-
Lysis buffer by sonication and protein homogenates were
quantiﬁed using BCA protein assay reagent (Thermo Fisher
Scientiﬁc). Tissue concentrations of cytokines were
measured using a proinﬂammatory cytokine screen (Meso
Scale Discovery, Rockville, MD). Assays were performed
according to the manufacturer’s instructions. Cytokine
concentrations were normalized to total protein
concentration.
Quantiﬁcation and Statistical Analysis
Data are expressed as means  SEM. Statistical analyses
were performed with GraphPad Prism software version
7.0 (GraphPad Software, La Jolla, CA) using a two-tailed
unpaired t-test for direct comparisons, and one-way or two-
way analysis of variance with Tukey’s test for multiple
comparisons. Statistical differences are reported as signiﬁ-
cant when P < 0.05.1186Results
Tryptophan-Indole Metabolism Is Altered in Murine
and Human Colitis
To better understand microbe-derived factors that contribute
to intestinal homeostasis, a comprehensive, unbiased screen
of serum and colonic tissue metabolites was performed from
healthy and DSS colitic mice. Mice were administered DSS
via drinking water, and serum and colonic tissue were
collected during peak disease (day 7). Of the microbe-
derived metabolites, most notable were decreases in
tryptophan-indole metabolites in both serum and colons of
colitic mice compared with mice administered water alone
(Figure 1A). Tryptophan is metabolized through various
pathways, including the indole pathway, resulting in de-
rivatives that are produced from metabolism by gut micro-
biota (Figure 1B). Colitis profoundly altered tryptophan
metabolism, speciﬁcally revealing a selective decrease in
indole metabolites. To validate this mass
spectrometryebased metabolite screen, an HPLC-based
protocol was developed using electrochemical detection
methods (Figure 1C). Eight- to 10-weekeold C57BL/6 mice
were administered water or 2.5% DSS ad libitum for 9 days.
DSS was then removed and mice were allowed to recover
for 2 days before euthanasia. Serum indole metabolites were
proﬁled by EC-HPLC (Figure 1D). Serum indole and IPA
levels were signiﬁcantly decreased in actively colitic ani-
mals (P < 0.05). A marked decrease in serum IAld was also
observed (P Z 0.09). It is notable that overall, tryptophan
levels in DSS colitis actually increase (Figure 1A), sug-
gesting that the ﬁndings of indole depletion are not a result
of diminished tryptophan absorption.
Guided by results of indole depletion in active murine
colitis, we attempted to translate our results to human pa-
tients. Here, the EC-HPLC method was used to quantify
various indole metabolites in serum samples from patients
with UC. For these purposes, serum samples from healthy
controls (n Z 20), subjects with active UC (n Z 15), and
subjects with UC in remission (n Z 20) were proﬁled
(Table 2). This analysis revealed that serum IPA was
deceased by nearly 60% in subjects with active UC
compared with healthy controls (P < 0.05) (Figure 1E).
Notably, this IPA deﬁciency normalized in UC patients in
remission, implicating IPA as both a biomarker for active
UC as well as an indicator of disease remission in human
UC. Based on these ﬁndings, the role of indole and
metabolites IPA and IAld on intestinal epithelial function
was further studied.
Indole Metabolites Induce IL-10R1 Expression on
Intestinal Epithelia and Improve Barrier Formation
We have previously shown that tryptophan metabolites are
important regulators of IL-10R1 in IEC.23 Guided by our
unbiased metabolomic proﬁle of serum and colon tissueajp.amjpathol.org - The American Journal of Pathology
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Figure 1 Tryptophan metabolism is altered in murine and human colitis. A: Relative levels of indole metabolites in serum and whole colon tissue of mice
receiving either water or 3% dextran sodium sulfate (DSS) for 7 days. Metabolites were measured by liquid chromatographyemass spectrometry and gas
chromatographyemass spectrometry analysis. B: Condensed pathway of tryptophan metabolism to indole and indole derivatives. C: EC-HPLC analysis of indole
metabolites in serum of mice receiving either water or 2.5% DSS for 9 days. D: Concentrations of indole metabolites in serum of mice receiving either water or 2.5%
DSS for 9 days. E: Indole-3-propionic acid (IPA) levels in serum samples from healthy controls (Con), subjects with active ulcerative colitis (UC), and subjects with UC
in remission (Rem) proﬁled by EC-HPLC. Data are expressed as means SEM (A, D, and E). nZ 5 (A, mice per treatment group, and D, water treatment); nZ 10 (D,
DSS treatment); nZ 20 (E, control and remission); nZ 15 (E, UC). *P < 0.05, **P < 0.01, t-test and one-way analysis of variance. IAld, indole-3-aldehyde.
Indoles and Intestinal Homeostasisfrom healthy and DSS-colitic mice, and our recent work
identifying the epithelial interleukin-10 receptor as the
dominant signature for resolution of inﬂammation in DSS
colitis,6,7 it was hypothesized that indole-containing tryp-
tophan metabolites regulate intestinal homeostasis via
regulation of epithelial IL-10R1 expression. To examine the
induction of IL-10R1 in response to indole metabolites, T84
IEC were exposed to IPA or IAld for 6 hours; real-time
quantitative PCR of IL-10R1 transcript levels showed a
concentration-dependent induction of IL-10R1 (Figure 2A).
These ﬁndings were not limited to colonic cancer cell lines.
HIOs are complex, three-dimensional spheroid tissues
derived from human pluripotent stems cells19 and contain
the majority of functional epithelial cell types (ie, enter-
ocytes, goblet, Paneth, enteroendocrine, intestinal stem
cells) and structures (ie, brush borders of microvilli, crypt-
like structures, and a mesoderm layer) comprising the
human small intestine.24 HIOs treated with IPA exhibited
increasing levels of IL-10R1 transcript, with signiﬁcant
induction at 24 hours (P < 0.001) (Figure 2B). Further
analysis revealed a prominent induction of IL-10R1 protein
expression in T84 IEC exposed to IPA and IAld
(Figure 2C).
The inﬂuence of the metabolite IAld on barrier formation
in T84 cell monolayers was further examined, as ourThe American Journal of Pathology - ajp.amjpathol.orgprevious work has demonstrated that IL-10 signaling is
important in IEC barrier development and maintenance.7,23
Cells exposed to both IAld and IL-10 exhibited signiﬁ-
cantly increased barrier formation at 72 hours compared
with untreated cells as measured by transepithelial electrical
resistances (P < 0.01) (Figure 2D). Further, IAld in com-
bination with IL-10 (10 ng/mL) signiﬁcantly induced sup-
pressor of cytokine signaling 3 (SOCS3), an
IL-10eresponsive gene that has been found to be protective
in intestinal inﬂammation25 (P < 0.05) (Figure 2E). From
this perspective, it is notable that SOCS3 was not induced
by IL-10 alone as a result of nearly undetectable levels of
IL-10R1 at baseline.6,7 Overall, these results identify indole
metaboliteedependent induction of the epithelial IL-10R1
as a target pathway for mucosal homeostasis.
Loss of Indole-Dependent IL-10R1 Induction in Cells
Lacking ARNT
The mechanism of indole signaling in intestinal epithelia
was studied next. Others have shown that tryptophan me-
tabolites function as endogenous ligands for AHR.26 To
determine the relative contribution of AHR to indole
signaling, shRNA knockdown was used to deplete the AHR
dimeric partner ARNT, and IL-10R1 induction was1187
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Figure 2 Indole metabolites improve barrier
formation and induce IL-10R1 on intestinal
epithelia. A: Real-time quantitative PCR (qPCR) of
IL-10R1 transcript levels in T84 cells treated with
indole-3-propionic acid (IPA) or indole-3-aldehyde
(IAld) at varying concentrations for 6 hours.
B: Human intestinal organoids treated with
1 mmol/L IPA over 24 hours. C: Western blot anal-
ysis of IL-10R1 levels in T84 cells treated with IPA at
varying concentrations for 6 hours or in response to
1 mmol/L IAld over 24 hours. D: Transepithelial
electrical resistance of T84 cells treated with IAld
(1 mmol/L), IL-10 (10 ng/mL), or a combination of
both was measured over 72 hours. E: qPCR of SOCS3
transcript in T84 cells treatedwith IAld for 12 hours,
followed by treatment with IL-10 for 6 hours. Data
are expressed as the average TEER SEM (D) and as
means SEM (A, B, and E). nZ 3 (D, samples, and
E, experiments). *P < 0.05, t-test, **P < 0.01
versus untreated cells, two-way analysis of
variance, and ***P < 0.001, t-test. þctrl,
6-formylindole[3,2-b] carbazole at 1 mmol/L; TEER,
transepithelial electrical resistance; Veh, vehicle.
Alexeev et alexamined as an endpoint. Lentiviral shRNA-mediated
knockdown of ARNT (shARNT) in T84 IEC resulted in
signiﬁcantly reduced ARNT mRNA expression (81%  5%
decrease; P < 0.01) relative to cells containing a non-
template control (shNTC) (Figure 3A). A broaderA B
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1188examination of classical AHR-ARNT target genes26e28
revealed that transcript levels of cytochrome P450 family
1 subfamily A member 1 (CYP1A1) and cytochrome P450
family 1 subfamily B member 1 (CYP1B1) were signiﬁ-
cantly increased in shNTC cells treated with IAld comparedFigure 3 IL-10R1 expression is not induced by
cells lacking aryl hydrocarbon receptor (AHR)
binding partner aryl hydrocarbon receptor nuclear
translocator (ARNT). A: Lentiviral shRNA-mediated
knockdown of ARNT (shARNT) in T84 intestinal
epithelial cells relative to T84 cells containing a
nontemplate control (shNTC). B: Transcript levels
of cytochrome P450 family 1 subfamily A member
1 (CYP1A1) and cytochrome P450 family 1 sub-
family B member 1 (CYP1B1) by real-time quan-
titative PCR (qPCR) in shNTC and shARNT T84 cells
following indole-3-aldehyde (IAld) treatment for
12 hours. C: qPCR analysis of IL-10R1 expression
in shNTC and shARNT T84 cells treated with 1
mmol/L IAld for 24 hours. D: Western blot analysis
of IL-10R1 levels in ARNT knockdown T84 cells.
Conﬂuent monolayers of T84 cells were treated
with IAld for 24 hours. E and F: Protein expression
was quantiﬁed by densitometry (E) and normal-
ized to b-actin. (F) qPCR of IL-10R1 transcript
levels in shNTC and shARNT T84 cells treated with
AHR inhibitor (AHRi, 10 mmol/L), IAld (1 mmol/
L), or both for 24 hours. Data are expressed as
means  SEM (AeC, E, and F). nZ 3. *P < 0.05,
**P < 0.01 versus untreated shNTC, t-test. tx,
treatment; Veh, vehicle.
ajp.amjpathol.org - The American Journal of Pathology
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Figure 4 Bacterial indole production induces
IL-10R1. A: Indole production test of cultures
from E. coli K12 WT, tnaA, and tnaB mutants; plus
sign indicates presence of indole. B: EC-HPLC
chromatogram of supernatants collected from E.
coli K12 WT and E. coli DtnaA. C: T84 cells were
treated for 24 hours with serially diluted super-
natants from E. coli WT or E. coli DtnaA cultures
grown to stationary phase, followed by media
replenishment. Germ-free mice were colonized
with E. coli WT or E. coli DtnaA for 2 weeks fol-
lowed by euthanasia. D and E: Indole concentra-
tions in cecal contents were validated by HPLC in
vehicle and colonized mice (D), and RNA was
extracted from colons for real-time quantitative
PCR analysis of Il10r1 expression (E). Data are
expressed as means  SEM (D and E). n Z 5 (D
and E, PBS and E. coli DtnaA); nZ 4 (D and E, E.
coli WT). *P < 0.05, **P < 0.01, t-test. þ ctrl,
interferon-g at 10 ng/mL; M, molecular marker;
PBS, phosphate-buffered saline; sup, supernatant;
tx, treatment.
Indoles and Intestinal Homeostasiswith untreated shNTC cells. Both targets were also signiﬁ-
cantly increased in the IAld-treated shNTC compared with
shARNT T84 IEC following IAld treatment (P < 0.01,
P< 0.05, respectively) (Figure 3B). Analysis of these ARNT-
deﬁcient cells revealed a prominent decrease in IAld-
dependent induction of IL-10R1 transcript and protein
(P < 0.05) (Figure 3, CeE). The AHR small-molecule in-
hibitor, CH-223191, serves as a speciﬁc AHR antagonist.
shNTC and shARNTT84 IECwere exposed to IAld (1mmol/
L), CH-223191 (10 mmol/L), or in combination for 24 hours.
IAld treatment alone signiﬁcantly increased IL-10R1
expression at 24 hours. CH-223191 signiﬁcantly reduced
IAld-mediated IL-10R1 induction, supporting the hypothesis
that IAld modulates IL-10R1 expression via an AHR-
mediated mechanism (P < 0.05) (Figure 3F). These results
suggest that the AHR pathway is involved in the indole
metaboliteedependent expression of IL-10R1 in IEC.
Bacterial Indole Production Induces IL-10R1
Whether microbe-derived sources of indole could similarly
regulate epithelial target genes was examined next. Indole
production was targeted in E. coli. Indole is synthesized
from tryptophan by microbial tryptophanase.29 UsingThe American Journal of Pathology - ajp.amjpathol.orgKovac’s reagent to test for the presence of indole, an E.
coli K12 strain (E. coli BW25113; WT) clearly produced
indole (Figure 4A), whereas deletion of the tryptophanase
gene (DtnaA) revealed a lack of detectable indole.
Conversely, deletion of one of the tryptophan transporters
(DtnaB) did not compromise indole production
(Figure 4A). To validate these observations, the presence
of indole in cell-free supernatants of bacteria was exam-
ined by EC-HPLC. Although E. coli WT bacteria exhibited
readily detectable levels of indole, metabolism of trypto-
phan to indole was completely abolished in E. coli DtnaA
(Figure 4B). To test the activity of this microbial-derived
indole, cell-free supernatants from E. coli WT and DtnaA
mutant were serially diluted and exposed to T84 IEC for
24 hours. Supernatants from E. coli WT readily induced
IL-10R1 protein expression, whereas minimal IL-10R1
induction was observed in cells exposed to E. coli DtnaA
supernatant (Figure 4C).
These ﬁndings were extended to an in vivo model. The
function of indole-producing bacteria was examined on
epithelial IL-10R1 in germ-free mice. Germ-free mice were
colonized with E. coli WT or E. coli DtnaA for 2 weeks
followed by euthanasia. Fresh fecal pellets were collected
periodically for plating to ensure equal colonization,1189
Alexeev et alquantiﬁed as bacterial colony forming units per gram of
feces (data not shown). Indole concentrations in cecal con-
tents were validated by HPLC in vehicle and colonized
animals. Mice monocolonized with E. coli WT displayed
signiﬁcantly increased cecal indole, whereas negligible
levels were measured in phosphate-buffered salinee and E.
coli DtnaAegavaged animals (P < 0.01) (Figure 4D).
Further, colons were harvested and RNA extracted for real-
time quantitative PCR analysis. This strategy revealed that
mice monocolonized with E. coli WT displayed signiﬁ-
cantly increased colonic il10r1 expression, whereas no
signiﬁcant il10r1 induction was observed in colon tissue of
mice colonized with E. coli DtnaA mutant (P < 0.05)
(Figure 4E). Taken together, these in vitro and in vivo
results strongly support the hypothesis that microbe-derived
indoles promote epithelial homeostasis.
IPA Improves DSS Colitis Outcomes
Given the observation that indole metabolites are signiﬁ-
cantly decreased in active colitis, the therapeutic potential ofWater
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C
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D
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water or 2.5% DSS  IPA ad libitum for 9 days. DSS was then removed and mic
A: Concentration of IPA in colons of mice receiving DSS  IPA for up to 9 days. B:
and eosinestained colonic sections isolated from water-treated, water/IPA-trea
toxylin and eosinestained colonic sections. EeG: Colon tissue was homogenized
analysis [interferon-g (IFN-g; E); tumor necrosis factorea (TNF-a; F); and IL-1b
**P < 0.01, and ***P < 0.001, two-way analysis of variance and t-test. Origina
1190IPA was tested in murine colitis outcomes. For these pur-
poses, mice were administered either normal drinking water,
DSS (2.5% wt/vol), or a combination of DSS and IPA
(0.1 mg/mL) in drinking water for 9 days, followed by DSS
removal and a 2-day recovery. To verify that oral adminis-
tration normalized IPA levels, colonic IPA was quantiﬁed by
EC-HPLC. This analysis revealed that although DSS colitic
mice displayed signiﬁcantly lower levels of IPA, oral
administration of IPA normalized colonic levels of this
metabolite (P < 0.01) (Figure 5A). Under these treatment
conditions, DSS/IPA-treated animals displayed signiﬁcantly
less reduction in colon length, a marker of intestinal
inﬂammation, compared with DSS-treated animals
(P < 0.05) (Figure 5B). Histologic analysis revealed that
DSS/IPA-treated mice displayed attenuated inﬂammatory
inﬁltration and decreased loss of architecture in comparison
with mice treated with DSS alone, which displayed
pronounced loss of epithelium and tissue architecture
(Figure 5C). These differences resulted in greater histopath-
ologic severity scores (P < 0.001) (Figure 5D). Tissue
cytokine levels were also examined in these mice.Water Water/IPA
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Indoles and Intestinal HomeostasisProinﬂammatory cytokine levels were dramatically increased
in DSS-treated mice, speciﬁcally IFN-g (P < 0.05)
(Figure 5E), tumor necrosis factor-a (TNF-a) (P < 0.01)
(Figure 5F), and IL-1b (P < 0.05) (Figure 5G), whereas
cytokine levels in DSS/IPA-treated mice were similar to mice
administered water alone. Similarly, IL-10 levels were
signiﬁcantly increased in DSS-treated mice, though IPA
administration did not alter levels of this cytokine
(Supplemental Figure S1). Further, IPA administration
increased transcript and protein levels of AHR target genes
(Supplemental Figure S2). Taken together, these results
indicate that therapeutic normalization of IPA during active
colitis attenuates disease and promotes intestinal
homeostasis.Discussion
Recent efforts to deﬁne the complex nature of IBD have
focused on the contribution of the host microbiota. It is now
established that altered microbial composition, termed dys-
biosis, is strongly associated with IBD30 and other intestinal
diseases.31 Such dysbiosis is thought to alter the immune
response and inﬂuence epithelial function, resulting in
increased intestinal permeability.32 The particular compo-
nents of the microbiome that promote disease and distin-
guish phenotypes are not well understood. In the current
work, we sought to identify and characterize microbial-
derived metabolites that contribute to colonic disease and
homeostasis.
Immunometabolism is an area of signiﬁcant interest in
mucosal inﬂammation.33 Guided by an unbiased metab-
olomic proﬁle of serum and colon tissue from healthy and
DSS-colitic mice, a signiﬁcant shift in tissue-associated,
microbiota-derived indole derivatives was identiﬁed. This
study shows that tryptophan does not decrease in murine
colitis. In fact, tryptophan levels signiﬁcantly increased in
colons of colitic mice. On the basis of these ﬁndings, we
believe the observed decrease of indole metabolites to be a
result of a selective depletion of tryptophan-indole metab-
olites due to dysbiosis, rather than poor absorption of
tryptophan.
Indole is produced from the action of microbial trypto-
phanase on tryptophan to produce indole, pyruvate, and
ammonia via a b-elimination reaction.34 Microbes that
express tryptophanase have the capacity to utilize trypto-
phan as a source of nitrogen, carbon, and energy.35 The
tnaA gene, encoding tryptophanase, is highly conserved
among Gram-negative indole-producing species, including
Citrobacter, Morganella, Klebsiella, Providencia, and
Haemophilus inﬂuenzae type b.36 The presence of tnaA is
strongly associated with virulence of H. inﬂuenzae.37 At
present, we do not know the nature of indole deﬁciencies
associated with active inﬂammation, though our work is
consistent with a study demonstrating that bacterial
fermentation metabolites are less abundant in patients withThe American Journal of Pathology - ajp.amjpathol.orgIBD compared with healthy controls.38 Additionally, Wlo-
darska et al39 have recently shown that microbes of IBD
patients have a reduced ability to cleave intestinal mucins
and metabolize tryptophan. Such a precedent exists for other
microbiota-derived metabolites. For example, studies
investigating dysbiosis in IBD have identiﬁed lower con-
centrations of luminal short chain fatty acids and signiﬁcant
depletion of butyrate-producing organisms (eg, speciﬁc
Faecalibacterium and Roseburia genera) with active colonic
disease.40e42 It is therefore likely that the observed
decreases in indole metabolism reﬂect inﬂammation-
associated dysbiosis.
Some evidence exists that microbial-derived indole and
indole metabolites could be anti-inﬂammatory. For instance,
Shimada et al43 demonstrated that indole administration to
germ-free mice increased the expression of some epithelial
tight junction proteins and attenuated weight loss in a DSS
colitis model. No mechanisms were evaluated to describe
these changes elicited by indole. Moreover, Venkatesh
et al44 have shown that IPA is a ligand for the pregnane
X receptor (PXR) and promotes intestinal barrier integrity
through down-regulation of epithelial TNFa, induction of
MDR1, and regulation of epithelial junctional complexes. It
is interesting to note that PXR, a member of the superfamily
of nuclear receptors, is under consideration as a novel drug
target in IBD.45 Further, Wlodarska et al39 have shown that
the metabolite indoleacrylic acid promotes intestinal barrier
function and mitigates inﬂammatory responses through
down-regulation of genes involved in inﬂammation and
oxidative stress. Conversely, it is also notable that some
indole derivatives have also been shown to be nephrotoxic.
For example, Devlin et al46 recently identiﬁed a widely
distributed family of tryptophanases produced by
commensal Bacteroides within the gut microbiota. They
demonstrate that microbe-derived indoles are modiﬁed by
the host to generate toxic renal levels of indoxyl sulfate and
that colonization with tryptophanase-deﬁcient Bacteroides
decreases systemic levels of indoxyl sulfate that may be
renal protective.
We translated these ﬁndings of shifts in indole meta-
bolism from murine colitis to human subjects. This analysis
revealed, for the ﬁrst time, that serum indole metabolites in
human subjects with active UC revealed a remarkable
similarity to mice with active colitis, with the exception that
human subjects were selectively deﬁcient in IPA and not
indole or IAld. The reason for this selective loss of IPA in
humans is not known. It should be noted that indole and
indole metabolites are produced by different pathways and
different bacteria. Because IPA is an indole derivative
conjugated to propionate, and propionate is among the short
chain fatty acids that become depleted in active human
IBD,40 it is possible that this selective depletion of IPA is
explained by an IBD-associated dysbiosis that results from
the combined depletion of both short chain fatty acide and
indole-producing microbiota. Further studies will be
necessary to deﬁne the nature of this observation.1191
Alexeev et alTherapeutic administration of oral IPA was protective in a
murine model of colitis. Animals that received IPA not only
exhibited fewer physical signs of disease, but also had
signiﬁcantly less damage to crypt structure and restricted
inﬂammatory inﬁltration. Indoles and other tryptophan
metabolites have been demonstrated to function as AHR
ligands.26,47,48 It is likely that as AHR ligands, these mol-
ecules directly inﬂuence the epithelial/immune cell axis. For
example, Zelante et al12 showed that IAld drives AHR-
dependent IL-22 production and mucosal protection.
Others have shown innate lymphoid cell AHR responses to
be protective in inﬂammation through the production of
IL-22.16 It is also noteworthy that intraepithelial lympho-
cytes localize in response to AHR stimulation by dietary
ligands,49 including speciﬁc CD4þCD8aaþ subsets of
intraepithelial T cells.50 The activity of AHR ligands on
intestinal epithelia is less well understood. We recently
demonstrated that similar to indole metabolites, other
tryptophan-derived metabolites, including kynurenine,
regulate epithelial IL-10R1 activity in an AHR-dependent
manner.23 Such activity was associated with protection in
colitis models and promoted epithelial wound healing.
These varied ligands suggest a promiscuous ligand-binding
pocket of AHR that is associated with agonistic activity.51
Moreover, these results suggest redundant mechanisms to
maintain expression of functional epithelial IL-10 receptors,
which have been shown to be essential for the development
and maintenance of barrier function.7
Finally, it is known that colitis occurs as the result of
immune cell responses to microbiota in susceptible hosts.52
These interactions are complex, involving multiple cell
types and a spectrum of metabolites. In this regard, the
contribution of cell types beyond the epithelium (eg,
immune cells) in regulation by bacterial-derived metabolites
in DSS cannot be ruled out. Rather, it is likely that these
metabolites have a plethora of actions on various cell types
in the mucosa. In our studies, we have limited this analysis
to the epithelium to allow for a deeper and more mechanistic
understanding of these signaling responses. These studies
provide strong evidence for the role of microbiota-derived
indole metabolites in anti-inﬂammatory pathways medi-
ated by IL-10 signaling in the intestinal epithelium. These
ﬁndings present new insight to our understanding of host-
microbial communication within the mucosa and identify
possible avenues for utilizing indoles as novel therapeutics
in mucosal disease.Acknowledgments
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